Pfizer (PFE) Given a $39.00 Price Target by BMO Capital Markets Analysts

Pfizer (NYSE:PFE) received a $39.00 price objective from BMO Capital Markets in a report issued on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective suggests a potential upside of 7.11% from the stock’s current price.

PFE has been the subject of several other reports. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. JPMorgan Chase & Co. set a $39.00 price target on Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. Jefferies Group set a $39.00 price target on Pfizer and gave the company a “neutral” rating in a report on Thursday, November 16th. Nord/LB restated a “neutral” rating on shares of Pfizer in a report on Tuesday, January 2nd. Finally, Morgan Stanley set a $41.00 price target on Pfizer and gave the company a “buy” rating in a report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company’s stock. Pfizer has a consensus rating of “Buy” and a consensus target price of $38.83.

Shares of Pfizer (NYSE:PFE) traded down $0.04 during trading hours on Monday, hitting $36.41. The stock had a trading volume of 16,011,600 shares, compared to its average volume of 14,910,983. Pfizer has a 1 year low of $30.90 and a 1 year high of $37.35. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The company has a market capitalization of $217,390.00, a P/E ratio of 22.34, a PEG ratio of 2.46 and a beta of 1.01.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. During the same period last year, the company earned $0.61 earnings per share. The company’s revenue was up .9% on a year-over-year basis. analysts expect that Pfizer will post 2.59 EPS for the current year.

Pfizer announced that its board has approved a stock repurchase program on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares of the company’s stock, valued at $3,827,946. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the transaction, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Insiders sold a total of 29,450 shares of company stock valued at $1,065,220 over the last quarter. 0.06% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in PFE. Janus Henderson Group PLC lifted its position in shares of Pfizer by 243.5% during the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock valued at $442,574,000 after buying an additional 9,339,749 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after buying an additional 9,239,499 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Pfizer during the 2nd quarter valued at about $268,389,000. Canada Pension Plan Investment Board lifted its position in shares of Pfizer by 249.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock valued at $359,871,000 after buying an additional 7,649,416 shares in the last quarter. Finally, Stifel Financial Corp lifted its position in shares of Pfizer by 5,413.5% during the 3rd quarter. Stifel Financial Corp now owns 7,360,192 shares of the biopharmaceutical company’s stock valued at $262,515,000 after buying an additional 7,226,697 shares in the last quarter. 69.74% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Pfizer (PFE) Given a $39.00 Price Target by BMO Capital Markets Analysts” was originally published by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.themarketsdaily.com/2018/01/10/pfizer-pfe-given-a-39-00-price-target-by-bmo-capital-markets-analysts.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply